)
)
Akero Therapeutics Investor Relations Material
Latest events
Study Result
Akero Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Akero Therapeutics Inc
Access all reports
Akero Therapeutics Inc. is a clinical-stage biopharmaceutical company primarily engaged in developing innovative treatments for serious metabolic diseases with significant unmet medical needs. The company's primary focus is on its lead product candidate, efruxifermin (EFX), which is in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH), a progressive liver disease characterized by fat accumulation and inflammation in the liver. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Key slides for Akero Therapeutics Inc
Study Update
Akero Therapeutics Inc
Study Update
Akero Therapeutics Inc
Latest articles
)
The Art of Portfolio Management: Lessons from Tom O'Hara
Tom O'Hara shares insights on stock picking, navigating market distractions, and the importance of one-on-one meetings with management teams.
4 Oct 2024
)
The Samsung Co-CEOs: Jong-Hee Han & Young-Hyun Jun
Samsung Electronics' dual-CEO structure, led by Jong-Hee Han and Young-Hyun Jun, is designed to navigate the complexities of its diverse business.
3 Oct 2024
)
Irwin Jacobs & Andrew Viterbi: Qualcomm's Pioneering Founders
In 1985, Irwin Jacobs and Andrew Viterbi co-founded Qualcomm, a leading company in telecommunications and semiconductor innovation.
3 Oct 2024
Ticker symbol
AKRO
Country
🇺🇸 United States